Login to Your Account

NDA Withdrawn, But Genta's Genasense Work To Continue

By Randall Osborne

Monday, May 17, 2004
Genta Inc.'s decision to reduce its work force as a way of focusing on the melanoma therapy Genasense, combined with the simultaneous move to withdraw the new drug application for that lead product, "might be confusing from an external perspective," conceded Joy Schmitt, spokeswoman for the company. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription